Best GLP-1 Telehealth Providers (2026): 8 Compared

Advertiser Disclosure: BestMedsHub may earn a commission when readers sign up with telehealth providers linked on this page. Editorial recommendations are independent. This article is informational only and is not a substitute for personalized care from a licensed clinician.

Best GLP-1 Telehealth Providers in 2026 (Quick List)

1. Ro Body – best overall, brand + compounded GLP-1, $145+/mo.
2. Hims Weight Loss – brand-name Wegovy and Ozempic, cash-pay, from $149/mo.
3. Remedy Meds – widest compounded selection (semaglutide + tirzepatide).
4. Henry Meds – fastest sign-up and shipping, $297/mo.
5. Mochi Health – best insurance support for branded Wegovy/Zepbound.
6. Sequence (by WW) – best behavioral + medication combo program.

Last updated: June 13, 2026 · Medically reviewed by Dr. Marcus Tan, MD · ~12 min read

In June 2026, the best GLP-1 telehealth provider depends on whether your insurance covers Wegovy or Zepbound. With coverage, Sequence by WeightWatchers Clinic is cheapest at $74/mo membership plus a $0-$50 copay. Without insurance, Mochi Health at $178/mo total (compounded semaglutide) is the lowest predictable price. Ro is the only platform that brokers both Wegovy and Zepbound brand fills. Avoid any provider that won’t show pricing before intake.

How we ranked GLP-1 telehealth providers in 2026

We started with 24 US telehealth companies that prescribe GLP-1s for weight loss and cut the list to eight using five gates: (1) actively prescribing a GLP-1 to new patients in June 2026, (2) public per-month pricing before payment, (3) licensed in 40+ states, (4) at least 12 months of operating history, and (5) no active state attorney-general enforcement action on the prescribing entity. We did not weight Trustpilot or BBB scores into the ranking itself; we surface them as separate decision signals because both can be gamed (BBB scores skew low for any company with a complaint-driven escalation path).

Each provider was scored on four pillars: predictable cash price (do you know your total monthly bill before checkout?), brand vs. compounded mix (does the patient have a legal, FDA-approved finished-drug option?), refund and cancellation transparency, and clinician model (are visits with US-licensed MDs/DOs/NPs, and is asynchronous-only care offered as a choice rather than a default?). Detailed methodology is on our weight-loss comparison hub.

The 2026 landscape: shortage is over, compounding rules tightened

The single biggest change since most “best GLP-1 telehealth” lists were last updated is regulatory. Semaglutide came off the FDA shortage list on Feb 21, 2025; tirzepatide had resolved earlier, on Dec 19, 2024. Mass 503B compounding from the bulks list ended through transition windows that closed by May 22, 2025. As of June 2026, 503A patient-specific compounding remains legal under FDCA Section 503A, which is why providers like Mochi, Henry Meds, and Remedy Meds can still dispense compounded semaglutide or tirzepatide on a per-prescription basis.

That window may be narrowing. On April 30, 2026, the FDA published a Federal Register notice proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The public comment period runs through June 29, 2026. Two of the largest US compounding manufacturers (ProRx and BPI Labs) ceased GLP-1 production earlier this year, and Eli Lilly’s April 2025 lawsuit against Henry Meds over compounded tirzepatide marketing is still active. If you’re choosing a compounded GLP-1 telehealth provider in 2026, you’re choosing a product that is legally distinct from the FDA-approved finished drug and may face supply disruption later this year. For the full regulatory walkthrough, see our companion guide on Wegovy vs. Zepbound.

Best overall (with insurance): Sequence by WeightWatchers Clinic

Sequence — rebranded after WeightWatchers acquired the platform for $132M in December 2023 — quietly became the cheapest credible path to a brand-name GLP-1 in 2026, but only if you have commercial insurance that covers Wegovy or Zepbound. Membership is $25/mo for the first three months on a 12-month commitment, then $74/mo. Medication is billed separately. With commercial insurance and the manufacturer savings card, eligible patients pay $0-$50/mo for the drug itself, which puts an insured Sequence patient at roughly $74-$124/mo all-in.

Sequence stopped offering compounded GLP-1s in May 2025 and is now brand-only. That’s a feature, not a bug: you’re getting Wegovy or Zepbound dispensed through a licensed retail or specialty pharmacy under the FDA-approved label. For brand Wegovy or Ozempic, medication is billed separately through the patient’s pharmacy benefit or a cash channel such as NovoCare ($349/mo standard self-pay). Sequence reported approximately 197,000 clinical members in Q1 2026, making it one of the largest brand-only GLP-1 telehealth providers in the US. (WeightWatchers’ parent emerged from a Chapter 11 restructuring in June 2025 and trades on Nasdaq as WW.)

The catch: month-to-month membership runs $149/mo, the 12-month commit comes with a real cancellation fee, and the program is structurally useless if your insurance refuses the prior auth. If you’re uninsured or your plan denies, skip to Mochi or Ro.

Best cheapest compounded: Mochi Health ($178/mo all-in)

For uninsured patients who want a predictable cash price, Mochi Health is the cleanest math in the category. $79/mo membership ($39 intro first month) plus $99/mo compounded semaglutide = $178/mo total. Compounded tirzepatide runs $199/mo, bringing the tirzepatide all-in to $278/mo. There is no separate visit fee, no shipping fee, no surprise lab markup. Mochi publishes outcomes claims of approximately 10% average body-weight loss in six months and 36 lb average loss in year one, with roughly 5-of-6 patient retention to month two.

[provider=”mochi-health”]

The risk profile is real. Mochi Health has more than 1,200 BBB complaints on file, and the Washington State Department of Health took action against Aequita Pharmacy, a Mochi-affiliated dispensing pharmacy. Trustpilot scores are mid-to-high but mixed. The product is compounded semaglutide or tirzepatide — not FDA-approved as a finished drug. If the FDA finalizes the April 30, 2026 Bulks List exclusion later this year, Mochi’s supply chain will require a substantive overhaul. We still rank Mochi first on cheapest-cash because the pricing is transparent and the platform has not had its prescribing license suspended; we’d recommend reading our full Mochi Health provider profile before signing up.

Best widest brand menu: Ro (Wegovy, Zepbound, Mounjaro)

Ro is the only major US telehealth platform that holds active partnerships with both Novo Nordisk and Eli Lilly. That means a single Ro intake can route an insured patient to Wegovy (semaglutide 2.4mg) or Zepbound (tirzepatide for obesity) depending on which drug the patient’s plan covers — and to Mounjaro for type-2 diabetes cases. Novo Nordisk dropped Hims from its preferred-partner list in June 2025 before the two reconciled in March 2026; Ro has held dual Novo and Lilly partnerships throughout, making it the most flexible brand-broker in the space.

[provider=”ro”]

Ro’s membership runs about $39 for the first month, then roughly $74/mo on an annual plan, and medication is billed separately at whichever channel the patient ends up on: NovoCare self-pay ($199 intro / $349 post-intro for Wegovy at most doses), LillyDirect ($299-$449/mo for Zepbound vials with a 45-day refill cadence), or a commercial-insurance copay route with the manufacturer savings card pulling cost to as low as $25/mo. For cash-pay patients we’d still send you to Mochi; for insured patients who want optionality across brand drugs, Ro is the right answer. Full pricing math is in our Wegovy vs. Zepbound comparison.

Best for tirzepatide cash-pay: Henry Meds vs. Remedy Meds

Both Henry Meds and Remedy Meds advertise compounded tirzepatide from $199/mo. The decision between them is mostly about which set of warning lights you can tolerate.

Henry Meds publishes a Trustpilot score of 4.5/5 across roughly 12,490 reviews. Its BBB rating is F, with 25 of its 208 filed complaints left unanswered. Eli Lilly sued Henry Meds in April 2025 over compounded tirzepatide marketing claims, and that case is ongoing. Compounded semaglutide runs $197-$397/mo by dose; oral semaglutide is $99-$149/mo. The advertised “from $179” price typically refers to liraglutide or a 12-month prepay.

Remedy Meds runs $189-$299/mo for compounded semaglutide with bundled visits, labs, and shipping. Some Remedy plans now route insured patients to brand Wegovy or Zepbound, which is unusual for a primarily-compounded platform. Read our full Remedy Meds review for the side-by-side.

[provider=”remedy-meds”]

If you want compounded tirzepatide and you’d rather not be a third-party plaintiff witness, Remedy Meds is the safer choice in 2026. If you want the lowest-possible advertised price and you’re comfortable with the regulatory and litigation risk, Henry Meds remains in the conversation. We’d send most readers to Remedy Meds.

Best for accountability: Teladoc Health

Teladoc Health is structurally different from every other provider on this list. It’s a publicly-traded multispecialty telehealth company (NYSE: TDOC) that wraps GLP-1 prescribing inside a full primary-care relationship. You’re not signing up for a weight-loss product; you’re signing up for ongoing PCP-style care with a licensed clinician who can also prescribe Wegovy or Zepbound. Pricing is variable — most patients access Teladoc through an employer health plan or commercial insurance, with copays in the $0-$89 range depending on plan design.

[provider=”teladoc-health”]

Teladoc does not prescribe compounded semaglutide or tirzepatide. The brand-drug route runs through commercial insurance plus the manufacturer savings card, which puts most insured patients in the $25-$50/mo range for medication itself. If you have employer-sponsored Teladoc access and your plan covers GLP-1s, this is meaningfully cheaper than any compounded path and avoids the regulatory uncertainty entirely. See our Teladoc Health review for plan-design details.

Side-by-side comparison table

Use-case decision tree: which provider for which patient profile

Insured (commercial plan covers Wegovy or Zepbound), BMI 30+: Sequence by WeightWatchers Clinic for cheapest-insured. Teladoc if you have employer-sponsored access. Ro if you want flexibility between Wegovy and Zepbound depending on which one your plan prefers.

Uninsured or insurance denies, wants the predictable monthly bill: Mochi Health for compounded semaglutide at $178/mo. Step up to compounded tirzepatide at $278/mo if your clinician thinks tirzepatide is the better molecule for your phenotype. Remedy Meds as the backup if Mochi denies or is out of stock for your dose.

Uninsured but wants brand-name only: Ro routing to NovoCare ($199 intro / $349 post-intro for Wegovy) or LillyDirect ($299-$449 for Zepbound vials). Full math in our Wegovy vs. Zepbound comparison.

Type-2 diabetes patient on Medicare: Stay with your existing endocrinologist or PCP and route Mounjaro or Ozempic through Medicare Part D. The July 1, 2026 GLP-1 Bridge program will cover Wegovy and Zepbound KwikPen (not vials) for eligible Medicare beneficiaries.

Cardiovascular comorbidity: Wegovy has the only FDA-approved cardiovascular outcome label in the class. See our companion guide on GLP-1s for heart health for the SELECT-trial data and prescribing logic.

What we did NOT recommend and why

We dropped 16 providers from this list. Four representative reasons: (1) Pricing hidden behind intake: we won’t recommend any provider that requires payment before disclosing the monthly medication cost. (2) Non-US prescribers: several “telehealth” companies route prescriptions through offshore physicians; that’s not legal GLP-1 prescribing in the US. (3) Active state enforcement: two compounding pharmacies on the original list have active state attorney-general actions; we removed those. (4) “Free GLP-1” landing pages: these are uniformly bait-and-switch funnels into compounded semaglutide priced above $300/mo once the actual intake completes.

For a deeper read on what the absence of a published Wegovy/Zepbound cash price means, see the cost-focused companion in this batch: Wegovy vs. Zepbound cost 2026.

Frequently Asked Questions

Sources

• NovoCare Wegovy patient pricing (verified June 2026)
• Lilly Zepbound pricing (verified June 2026)
• FDA: Policies for compounders as GLP-1 supply stabilizes
• WeightWatchers Clinic plans (verified June 2026)
• Eli Lilly press release: Zepbound vial price cut (Feb 23, 2026)
• BBB profile: Mochi Health
• BBB profile: Henry Meds

Medical disclaimer: Information here is educational only. GLP-1 medications can cause serious side effects including pancreatitis, gallbladder disease, and thyroid C-cell tumors (boxed warning). Consult a licensed clinician before starting, switching, or stopping any prescription weight-loss medication.